SCHEMBL22360254

SCHEMBL22360254

CC/C=N\NCc1ccn(C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.43
KDM1A O60341 1/20 0.34
POLB P06746 1/20 0.33
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
NAMPT P43490 1/20 0.32
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
HPGDS O60760 1/20 0.32
KDM4E B2RXH2 2/20 0.32
ALDH1A1 P00352 2/20 0.32
NPC1 O15118 1/20 0.32
MAPT P10636 1/20 0.32
RAB9A P51151 1/20 0.32
GFER P55789 1/20 0.32
KCNH2 Q12809 2/20 0.31
GRIN2B Q13224 1/20 0.31
PDE10A Q9Y233 1/20 0.31
KMT2A Q03164 2/20 0.31
OPRM1 P35372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22360305 0.83 EPHX2 (0.45) EPHX2KDM1APOLBDDB1CRBN
SCHEMBL178474 0.71
SCHEMBL6668265 0.68 KDM1A (0.48) EPHX2KDM1ADDB1CRBNNAMPT
SCHEMBL17788638 0.67 EPHX2 (0.49) EPHX2KDM1ADDB1CRBNNAMPT
SCHEMBL3305842 0.66 EPHX2 (0.47) EPHX2KDM1ADDB1CRBNNAMPT
SCHEMBL31637548 0.66 EPHX2 (0.44) EPHX2KDM1ADDB1CRBNNAMPT
SCHEMBL26269465 0.65 LMNA (0.46) EPHX2KDM1APOLBKMT2ALMNA
SCHEMBL26026716 0.65 EPHX2 (0.57) EPHX2KDM1ADDB1CRBNNAMPT
SCHEMBL15932464 0.65 NPSR1 (0.53) EPHX2DDB1CRBNNAMPTHPGDS
SCHEMBL21290463 0.65 EPHX2 (0.54) EPHX2KDM1ADDB1CRBNNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020167976-A1 THIENO[3,2-B] PYRROLE[3,2-D]PYRIDAZINONE DERIVATIVES AND THEIR USE AS PKM2 DERIVATIVES FOR THE TREATMENT OF CANCER, OBESITY AND DIABETES RELATED DISORDERS AGIOS PHARMACEUTICALS, INC. (US) 2020-08-20 WO disclosed